← 프로그램 목록
항체Phase 2Recruiting

atezolizumab (Tecentriq)

RocheGenentech

비교

Atezolizumab - 28 Day Cycle(Roche / Genentech)은 Endometrial Cancer 표적 항체로, Endometrial Cancer 영역에서 개발·상용화 중입니다. 작용기전: for heavily pretreated patients in need of improved therapies. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 33.3% (ClinicalTrials.gov NCT03337698). 차별점: novel mechanism of action for heavily pretreated patients in need of improved therapies.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

Endometrial Cancer

Endometrial Cancer

Recruiting

Technology

구조모아 · MMAE (auristatin)

oncolytic virus-based immunostimulatory gene therapy, combined with c

Vedotin on Brain Metastases in Urothelial Cance

novel mechanism of action for heavily pretreated patients in need of improved therapies

Mechanism of Action

for heavily pretreated patients in need of improved therapies

immune-mediated adverse events, and no new safety signals were identified

PD-L1) expression

resistance to hypomethylating agents (HMA) among patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CM

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 53건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 2, Phase 3 · Phase 2 · Phase 3 · Phase 1, Phase 2…
  • Status: Active, not recruiting · Recruiting · Completed
  • 주요 endpoint: Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 · Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1 · Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on RECIST v1.1 in bTMB PP1 · Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1 · Cohort E: Time in Response (TIR) as Assessed by the Investigator Based on RECIST v1.1
  • 등록된 결과: ORR 33.3%
  • 핵심: This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in par…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Atezolizumab - 28 Day Cycle은 어떤 치료제인가요?
Atezolizumab - 28 Day Cycle(Roche / Genentech)은 Endometrial Cancer 표적 항체로, Endometrial Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Atezolizumab - 28 Day Cycle의 임상 단계는?
Atezolizumab - 28 Day Cycle의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.